ライフサイエンスコーパス: TB

1 TB-DzT combines a multiplex PCR with single nucleotide p

2 A total of 23 studies reporting 593 TB cases occurring in 324,041 cancer patients between 19

3 A TB-sensitive cash transfer approach to increase all poor

4 le for preventing TB catastrophic costs as a TB-specific cash transfer approach to defray TB-related

5 A total of 86 participants from a TB-endemic setting, either HIV-infected or uninfected an

6 If cash transfers were provided with a TB-specific approach, alone they would be insufficient t

7 engthen their economic resilience (termed a "TB-sensitive" approach).

8 lds with a confirmed TB diagnosis (termed a "TB-specific" approach); or to increase income of househo

9 low TB = 59 K and a relaxed state well above TB.

10 non-sputum biomarker test to diagnose active TB for treatment initiation (TPP#1) and for a community-

11 During active TB in humans a spectrum of pulmonary granulomas with cen

12 e individuals that had recovered from active TB.

13 .9 years of follow-up, 1,186 incident active TB cases were identified among cohort participants.

14 ents (98% of all patients) the CIR of active TB decreased by 3 fold and 6.5 fold in hematologic and s

15 the lowest quartile, reduced risk of active TB was observed for the highest quartile of vitamin A in

16 ffic on mortality during treatment of active TB.

17 cted or uninfected and with latent or active TB (aTB), were screened using M.tuberculosis-specific MH

18 ed 32,875 patients in California with active TB and followed them throughout treatment.

19 conducted as part of the Zambia-South Africa TB and AIDS Reduction Study (2006-2010).

20 aimed at manipulating host immunity against TB.

21 Although TB-NTM coinfection may have been underdiagnosed, our res

22 the pathological interactions between DM and TB remain incompletely understood.

23 position of the foreign-born population) and TB transmission dynamics contribute to state-level diffe

24 ash transfers, and estimated TB-specific and TB-sensitive target populations.

25 tory oxidases that can be exploited for anti-TB drug development.

26 l wall, is the target for the frontline anti-TB drug isoniazid.

27 may reflect long-term effects of antibiotic TB treatment on the microbiome.

28 nostic strategy on initiation of appropriate TB treatment.

29 ulture-positive PTB initiated on appropriate TB treatment within 30 days were 76.5% in the laboratory

30 een systematically studied in HIV-associated TB.

31 We developed an individual-based TB transmission model representing a hypothetical popula

32 uated in India, our model generated baseline TB incidence and mortality of 157 (95% uncertainty range

33 nostic (BA) design and a traditional basket (TB) design that includes only biomarker-positive patient

34 thermal blocking state at temperatures below TB = 59 K and a relaxed state well above TB.

35 This weak discrimination between TB and non-TB groups was reflected in poor positive and

36 lanations for the discordant results between TB&S and WGS data, revealed the true phylogenetic relati

37 apevine, we compared the Tempranillo Blanco (TB) white berry somatic variant with its black berry anc

38 igns, there are sporadic outbreaks of bovine TB in regions declared TB free.

39 ) created from unerupted porcine tooth buds (TBs) can be used to guide reseeded dental cell different

40 Childhood TB diagnosis is challenging.

41 ind characteristics associated with clinical TB in meerkats.

42 but the mechanisms causing BBB damage in CNS TB are uncharacterized.

43 vel targets for host directed therapy in CNS TB.

44 ts further development to potentially combat TB in HIV-endemic areas.

45 s manage repeat patients or more complicated TB presentations.

46 related costs of households with a confirmed TB diagnosis (termed a "TB-specific" approach); or to in

47 sts only in poor households with a confirmed TB diagnosis.

48 MDR-TB was defined as culture-confirmed TB disease with resistance to at least isoniazid and rif

49 For confirmed-TB patients, half the variation in major clinical variab

50 itric oxide (NO) is important in controlling TB infection.

51 c outbreaks of bovine TB in regions declared TB free.

52 Demographic changes and declining TB transmission alone were insufficient to explain recen

53 th increased risk and IFNbeta with decreased TB risk.

54 h transfers may either be provided to defray TB-related costs of households with a confirmed TB diagn

55 TB-specific cash transfer approach to defray TB-related costs only in poor households with a confirme

56 icant (P < 10(-20)) for previously described TB markers, such as IP-10, LBP, FCG3B, and TSP4, and for

57 We retrospectively reviewed the Determine TB-LAM lateral flow assay (LF-LAM) results among human i

58 urrently possible to predict who may develop TB.

59 t is expensive, slow, and may under-diagnose TB dissemination.

60 erise the clinical phenotype of disseminated TB.

61 erification set (AUC of 0.92) to distinguish TB and non-TB samples.

62 one they would be insufficient to prevent DS TB catastrophic costs in 4 out of 6 countries, and when

63 ies, and when increased enough to prevent DS TB catastrophic costs would require a budget between $3.

64 Before cash transfers, DS TB-related costs were catastrophic in 6 out of 7 countri

65 58% of the estimated new drug-sensitive (DS) TB patients in 2016.

66 19%, and 28% increased risk of death during TB treatment [first quintile, referent; second quintile

67 e associated with increased mortality during TB treatment, although the findings were not statistical

68 conducted using the programmatic electronic TB treatment database.

69 be missed annually, and in view of WHO's end TB strategy endorsed by the health authorities of WHO Me

70 illar of the World Health Organization's End TB Strategy.

71 d income, mean cash transfers, and estimated TB-specific and TB-sensitive target populations.

72 pulmonary TB (PTB; 91.3%) and extrapulmonary TB (EPTB; 92.3%), and the sensitivities obtained for cul

73 ) for TBLH-BMD, and 39% (95% CI: 30-48%) for TB-LM, with a shared genetic component of 43% (95% CI: 2

74 -Printed Circuit Board (LoPCB) approach, for TB diagnosis based on cytokine detection.

75 n with HIV type 1 is a major risk factor for TB, and a better understanding of HIV-induced alteration

76 Despite substantial clinical need for TB prevention and treatment, pregnant women remain negle

77 re systematically confirmed or ruled out for TB by culture and clinical follow-up.

78 l methods can guide antibiotic selection for TB.

79 eful adjunctive, host-directed therapies for TB.

80 linically relevant host-directed therapy for TB.

81 As novel vaccines for TB are developed, venue-based vaccine delivery that targ

82 concentrated, protein-normalized urine from TB patients and non-TB controls, the CFP10 (EsxB) SOMAme

83 As GI TB can cause morphological alterations in and around the

84 ty for patients suspected of abdominal or GI TB.

85 stics are of the highest priority for global TB control.

86 bsent additional intervention in this group, TB incidence may not decline further.

87 r to increase income of households with high TB risk to strengthen their economic resilience (termed

88 T cell responses are still elusive for human TB.

89 izing lung lesions, widely observed in human TB.

90 sion compared to commonly used, immortalized TB cell lines and primary cells from term placenta.

91 Harvested mandibles with implanted TB constructs were fixed in formalin, decalcified, embed

92 be a useful research tool and could improve TB diagnosis and treatment.

93 In TB, lack of sexual transmission of rearranged chromosome

94 MMP activity in TB differs by HIV-1 status and compartment, and releases

95 te lung inflammation and bacterial burden in TB.

96 enarios that assumed contemporary changes in TB dynamics among the foreign-born - a declining rate of

97 ios projected a flattening of the decline in TB incidence by 2025 without additional resources or int

98 ifferent explanations for recent declines in TB incidence.

99 ics contribute to state-level differences in TB epidemiology.

100 Here, we demonstrate CD1b expression in TB granulomas and reveal a central role for meromycolate

101 rize drivers of state-level heterogeneity in TB epidemiology in the four U.S. states that bear half t

102 The median increase in TB during the periods off sunitinib was 1.6 cm (range, -

103 ential signals (P < 0.0276), particularly in TB patients with HIV coinfection.

104 ze the role that the private sector plays in TB patient care seeking and suggested a need for differe

105 wed an early decrease in glycerol release in TB d 4 (TB4) rats in relation to the control, followed b

106 ine structure influences T cell responses in TB-exposed individuals, and meromycolate alterations mod

107 and plasma analytes, comparing South Indian TB patients with and without DM to diabetic and non-diab

108 a prospective cohort study of HIV-1-infected TB patients at risk of TB immune reconstitution inflamma

109 In a macaque model of inhalation TB, suppression of IDO activity reduced bacterial burden

110 Despite intensive TB control campaigns, there are sporadic outbreaks of bo

111 ional component of T-cell immunity in latent TB and potential correlate of protection.

112 althy HIV-uninfected individuals with latent TB infection.

113 resistant individuals diagnosed with latent TB, and from susceptible individuals that had recovered

114 -attenuated strain, protected against lethal TB in macaques.

115 wed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combinat

116 Lower TB risk was seen for vitamin C intake among current smok

117 TB treatment duration from 6 to 2 mo lowered TB mortality by 3% (95% UR: 1%-6%), and shortening RR TB

118 and the adverse side effect profiles of many TB drugs, further investigation of lansoprazole as a pot

119 l size and duration, is not observed in Mc3r(TB/TB) mice.

120 incidence in persons treated for latent MDR -TB infection is unknown.

121 MDR-TB was defined as culture-confirmed TB disease with resi

122 The estimated MDR-TB incidence reduction was 90% (9%-99%) using data from

123 r clinically diagnosed cases treated for MDR-TB.

124 roach, we estimated that the majority of MDR-TB was due to the recent transmission of already-resista

125 MDR-TB to prevent further development of MDR-TB.

126 Better estimates of pediatric MDR-TB burden in the United States are needed and should inc

127 Most pediatric MDR-TB cases were female (n = 51 [62%]), median age was 5 ye

128 n potential underestimation of pediatric MDR-TB, we surveyed high-burden states for clinically diagno

129 targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.

130 e use of these drugs and for the shorter MDR-TB regimen in the pediatric population.

131 tiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness.

132 ead of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB)

133 evelop multidrug-resistant tuberculosis (MDR-TB) each year.

134 home to nearly 20% of the world's "missing" TB patients.

135 Given these new data, the National TB Program (NTP), operating through a decentralized heal

136 years) TB cases reported to the US National TB Surveillance System during 1993-2014.

137 ) freshly isolated nondecellularized natural TBs (nTBs).

138 atural products that represent promising new TB drug leads.

139 in-normalized urine from TB patients and non-TB controls, the CFP10 (EsxB) SOMAmer yielded the most s

140 This weak discrimination between TB and non-TB groups was reflected in poor positive and negative pr

141 set (AUC of 0.92) to distinguish TB and non-TB samples.

142 insufficient to explain recent trends in NYC TB incidence.

143 This estimated the probability of ocular TB for each patient in two versions, first with and then

144 The estimated probability of ocular TB was compared with treatment failure.

145 nts with clinical signs suggestive of ocular TB, 267 patients who had QFT and complete data were eval

146 in IP-10 levels (between day 0 and day 7 of TB therapy) to identify bacteriological status at diagno

147 patient care seeking and the availability of TB diagnostic and treatment services.

148 d the disproportionate demographic burden of TB among the population of adult males as a whole.

149 improving and shortening the long course of TB treatment.

150 ics and have implications for development of TB drug cocktails.

151 BI treatment could accelerate elimination of TB disease in the United States.

152 ed a spatial analysis of the epidemiology of TB among Singapore residents.

153 l to infer differences in natural history of TB and in future projections of TB.

154 Previous group history of TB increased the hazard by a factor of 4.29 (2.00-9.17,

155 ole was associated with reduced incidence of TB disease.

156 In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the

157 reatments generated, the projected number of TB deaths averted, and the projected number of unnecessa

158 ians should be alerted to the possibility of TB due to nosocomially acquired, catheter-related infect

159 tions in which the anticipated prevalence of TB (and HIV) is the highest.

160 tients, we aimed to report the prevalence of TB-blood-culture positivity, performance of rapid diagno

161 l history of TB and in future projections of TB.

162 udy of HIV-1-infected TB patients at risk of TB immune reconstitution inflammatory syndrome (TB-IRIS)

163 ta-analysis to estimate the relative risk of TB incidence and its 95% confidence interval.

164 We found a reduced risk of TB incidence with treatment for MDR-LTBI, suggesting eff

165 16S rDNA and metagenomic DNA sequencing, of TB cases during antimycobacterial treatment and followin

166 ial burden, pathology, and clinical signs of TB disease, leading to increased host survival.

167 he implications for the future trajectory of TB in the US remain unclear.

168 could accurately describe the trajectory of TB incidence since 2007.

169 apy strategy for prevention and treatment of TB-IRIS.

170 no significant difference between the IB or TB conjunctiva locations in terms of the effectiveness o

171 ther complications nor changes in PD, KT, or TB were observed.

172 ens and therefore cannot be used to rule out TB disease.

173 review and included countries' mean patient TB-related costs, mean household income, mean cash trans

174 mber of unnecessary treatments generated per TB death averted, if standard Xpert were switched to Xpe

175 favorable, at 372 unnecessary treatments per TB death averted (95% UR: 75, indefinite upper bound), a

176 y testing and open avenues for personalizing TB therapy.

177 We tested whether SCFAs contribute to poor TB control in a longitudinal cohort of ART-treated HIV-i

178 r cohort may enable us to accurately predict TB susceptibility.

179 conclusion, Nos2 (-/-) mice are a predictive TB drug development tool owing to their consistent devel

180 nts in appropriate management of presumptive TB patients in village clinics and township health cente

181 time new patient presenting with presumptive TB, which may not reflect how providers manage repeat pa

182 be as effective or affordable for preventing TB catastrophic costs as a TB-specific cash transfer app

183 a in the microbiome in persons with previous TB disease may reflect long-term effects of antibiotic T

184 oms and signs suggestive of active pulmonary TB that were systematically confirmed or ruled out for T

185 g HRCT criteria to diagnose active pulmonary TB were 95%, 40% and 1.4, respectively.

186 a cartridge for diagnosis of adult pulmonary TB may have different consequences in different clinical

187 We further find that after pulmonary TB infection, it still takes many days before such T cel

188 ions in vaccine strategies against pulmonary TB and other intracellular infections in the lung.

189 ticipants with previous or current pulmonary TB may have the potential for causing harmful postvaccin

190 All patients developed pulmonary TB, either alone or with extrapulmonary disease.

191 -detector HRCT chest in diagnosing pulmonary TB cases whose sputum smears are negative and making a c

192 ined for cases of culture-positive pulmonary TB (PTB; 91.3%) and extrapulmonary TB (EPTB; 92.3%), and

193 cted ocular tuberculosis (TB) by QuantiFERON-TB Gold In-Tube (QFT) tests using latent class analysis

194 Individuals who had a change in QuantiFERON-TB IFN-gamma values from less than 0.2 to greater than 0

195 mprove the consistency of serial QuantiFERON-TB testing algorithms and provide a data-driven definiti

196 tuberculin skin test (TST), the Quantiferon-TB Gold in-tube (QFT-GIT), and the T-SPOT.TB (T-SPOT).

197 RMP may recover its efficacy against RIF(R) TB.

198 occurrence of Rifamycin-resistant (RIF(R) ) TB, approximately 41% of which results from the RpoB S53

199 stics to a novel regimen's ability to reduce TB incidence and mortality, we sought to prioritize regi

200 to the corresponding regimens by 50% reduced TB and RR TB mortality by 2% (95% UR: 1%-4%) and 6% (95%

201 B treatment efficacy from 94% to 99% reduced TB mortality by 6% (95% UR: 1%-13%, half the impact of a

202 otentially identifying highly drug-resistant TB more quickly and simply than currently available meth

203 subjects with MDR/extensively drug-resistant TB subjects and sequenced the full gyrA and gyrB open re

204 men), and increasing the efficacy against RR TB from 76% to 94% lowered RR TB mortality by 13% (95% U

205 he time of novel regimen introduction and RR TB incidence and mortality of 6 (95% UR: 4-10) and 0.6 (

206 responding regimens by 50% reduced TB and RR TB mortality by 2% (95% UR: 1%-4%) and 6% (95% UR: 3%-10

207 by an estimated 32% (95% UR: 18%-46%) and RR TB mortality by 30% (95% UR: 18%-44%).

208 acy against RR TB from 76% to 94% lowered RR TB mortality by 13% (95% UR: 6%-23%).

209 An optimal RR TB regimen reduced RR TB incidence by an estimated 32% (

210 An optimal RR TB regimen reduced RR TB incidence by an estimated 32% (95% UR: 18%-46%) and R

211 g RR TB treatment from 20 to 6 mo reduced RR TB mortality by 8% (95% UR: 4%-13%), while reducing nona

212 ity by 3% (95% UR: 1%-6%), and shortening RR TB treatment from 20 to 6 mo reduced RR TB mortality by

213 ers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatm

214 approximately 300 sequentially diagnosed RR-TB patients per South African province, were drawn from

215 reatment delay among laboratory-diagnosed RR-TB patients.

216 Nationally, among the 2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53

217 ection with Xpert, a larger proportion of RR-TB patients overall have received treatment, with reduce

218 were newly diagnosed with RR-TB (no prior RR-TB diagnoses).

219 spectively; 92% were newly diagnosed with RR-TB (no prior RR-TB diagnoses).

220 ting all minimal targets only, increasing RS TB treatment efficacy from 94% to 99% reduced TB mortali

221 but still substantial impact: shortening RS TB treatment duration from 6 to 2 mo lowered TB mortalit

222 our U.S. states that bear half the country's TB burden: California, Florida, New York, and Texas.

223 both traditional biochemistry and serology (TB&S) and the kmer identification (ID) derived from the

224 d TB patients and corresponded with specific TB clinical phenotypes.

225 on-TB Gold in-tube (QFT-GIT), and the T-SPOT.TB (T-SPOT).

226 en reading frames in their respective sputum TB isolates.

227 ence on the time to development of end-stage TB.

228 sis among 127 HIV-infected patients starting TB treatment.

229 a dynamic transmission model of multi-strain TB epidemics in hypothetical populations reflective of t

230 vation or a decrease in imported subclinical TB - could accurately describe the trajectory of TB inci

231 d between 2005 and 2012 for drug-susceptible TB in Cape Town was conducted using the programmatic ele

232 immune reconstitution inflammatory syndrome (TB-IRIS), in Cape Town, South Africa.

233 emains the cornerstone of current short-term TB treatment.

234 Mismatches between the TB&S and kmer ID results were explained by the close phy

235 Together, we have built the TB Portals, a repository of socioeconomic/geographic, cl

236 is needed if we are committed to ending the TB epidemic.

237 tion estimated that nearly two-thirds of the TB patients in Indonesia had not been notified, and the

238 cm (range, -2.9 to 3.4 cm) compared with the TB immediately before stopping sunitinib.

239 ently required, however a major challenge to TB drug development is the lack of predictive pre-clinic

240 e insight into protective T cell immunity to TB.

241 ata suggest that increased susceptibility to TB disease could be related to a loss of circulating Th1

242 ore approaches to classify susceptibility to TB, we infected with MTB dendritic cells (DCs) from puta

243 time that FLA carrying M. bovis can transmit TB.

244 development of a clinical candidate to treat TB.

245 Tuberculosis (TB) due to Mycobacterium tuberculosis remains a major gl

246 Tuberculosis (TB) is a deadly infectious disease, which kills millions

247 Tuberculosis (TB) is a paramount example of a chronic infection in whi

248 Tuberculosis (TB) is an important and widespread disease of wildlife,

249 Tuberculosis (TB) is responsible for enormous global morbidity and mor

250 Tuberculosis (TB) is the fourth leading cause of death in Indonesia.

251 Tuberculosis (TB) treatment is long and complex, typically involving a

252 Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a maj

253 teady decline since the 1990s, tuberculosis (TB) incidence in New York City (NYC) and the United Stat

254 risk for progressing to active tuberculosis (TB) and have various sensitivities and specificities in

255 tum biomarker tests for active tuberculosis (TB) diagnostics are of the highest priority for global T

256 f an effective vaccine against tuberculosis (TB) is that the attributes of protective CD4(+) T cell r

257 n infectious diseases, such as Tuberculosis (TB).

258 BCG infection in the Barcelona tuberculosis (TB) program were reviewed from 1 January 2005 to 31 Dece

259 Bovine tuberculosis (TB) is a zoonotic disease caused by Mycobacterium bovis.

260 GS) is a newer alternative for tuberculosis (TB) diagnostics and is capable of providing rapid drug r

261 line antibiotic treatment for tuberculosis (TB), and it remains the cornerstone of current short-ter

262 In tuberculosis (TB), the innate inflammatory immune response drives tiss

263 can treat or prevent incident tuberculosis (TB) disease.

264 abetes mellitus (DM) increases tuberculosis (TB) risk and adverse outcomes but the pathological inter

265 ious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published data consist of small

266 with multidrug-resistant (MDR) tuberculosis (TB).

267 patients with suspected ocular tuberculosis (TB) by QuantiFERON-TB Gold In-Tube (QFT) tests using lat

268 monitor the long treatment of tuberculosis (TB) are lacking.

269 1 patients without evidence of tuberculosis (TB) coinfection.

270 RATIONALE: Administration of tuberculosis (TB) vaccines in participants with previous or current pu

271 sions that are the hallmark of tuberculosis (TB).

272 tuberculosis causes pulmonary tuberculosis (TB) and claims 1.8 million human lives per annum.

273 e causative agent of pulmonary tuberculosis (TB).

274 The Singapore Tuberculosis (TB) Elimination Program (STEP) was set up in 1997, and t

275 Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HI

276 s remain highly susceptible to tuberculosis (TB) and have an enrichment of oral anaerobes in the lung

277 ing levels of mortality due to tuberculosis (TB).

278 Worldwide, tuberculosis (TB) remains one of the most prevalent infectious disease

279 HIV type 1 (HIV-1)-infected and -uninfected TB patients and controls, and a prospective cohort study

280 fered between HIV-1-infected and -uninfected TB patients and corresponded with specific TB clinical p

281 tudy are that we could not determine whether TB disease was due to reactivation of latent infection o

282 ong 1164 specimens from 892 children in whom TB was excluded, strongly suggesting all Xpert MTB/RIF p

283 ins and carotenoids were not associated with TB risk.

284 ovel proteins not previously associated with TB.

285 murine inflammation model and macaques with TB to identify [(64)Cu]-labeled CB-TE1A1P-PEG4-LLP2A ([(

286 andidates, we subjected Nos2 (-/-) mice with TB to monotherapy before or after establishment of human

287 tment failure rate occurred in patients with TB uveitis treated with ATT.

288 diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and

289 al effect if given to people presenting with TB disease.

290 o diabetic and non-diabetic controls without TB.

291 ssment of PZA molecular diagnostics in M/XDR TB cases.

292 ic composition and evolution of MDR- and XDR-TB in the region, we sequenced and analyzed the genomes

293 MDR and XDR-TB isolates were significantly more likely to belong to

294 first- and second-line drugs in MDR and XDR-TB.

295 Our approach could enable testing for XDR-TB in point-of-care settings, potentially identifying hi

296 tuberculosis resistance mutations and M/XDR-TB treatment outcomes, limiting our current ability to e

297 drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

298 extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

299 ion of resistance within patients, while XDR-TB was acquired through both routes.

300 or newly diagnosed pediatric (age <15 years) TB cases reported to the US National TB Surveillance Sys